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a b s t r a c t
Low paraoxonase 1 (PON1) activity and carotid atherosclerosis have been suggested to be
important risk factors for dementia. However, the studies to date could not fully clarify the
relationship between PON1, carotid atherosclerosis and dementia. The present study aimed
to measure carotid atherosclerosis and PON1 activity in Alzheimer's Disease and to evaluate
the relationship between them. The study included 25 Alzheimer's patients and 25 control
subjects, for a total of 50 individuals. The study measured the serum PON1 activity and other
biochemical parameters and carotid atherosclerotic plaque values of the participants. The
mean paraoxonase activity (31.06  2.31 U/L) was signiﬁcantly lower in the Alzheimer's
group compared to the control group (59.05  7.05 U/L) (P < 0.001). Nonetheless, the carotid
plaque values were signiﬁcantly higher in the patient group (3.02  0.52 mm) compared to
the control group (1.84  0.45 mm) (P < 0.001). Furthermore, there was a negative correlation
(81.0%) between PON1 activity and carotid plaque in the overall study group (P < 0.05). Also
serum homocystein level was higher in the patient group (22.15  7.05) compared to the
control group (13.30  3.32). In conclusion, our ﬁndings show inverse association between
PON1 activity and carotid atherosclerosis in Alzheimer patients: the lower the PON1 activity
the more progressed the atherosclerotic process in AD.
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Alzheimer's disease (AD) is the most common cause of
dementia among individuals aged 65 and above and currently
affects more than 25 million people around the world. This
number is estimated to reach to 81.1 million by 2040 by
doubling every 20 years. AD is a progressive, neurodegenera-
tive disease characterized by the presence of several types of
amyloid plaque (Ab) and neuroﬁbrillary tangle in the brain,
associated with cognitive disorders and neuronal cell loss [1,2].
The exact cause of Alzheimer's disease is not clear; however,
genetic and environmental factors are believed to have an
effect on the development of the disease [3]. In recent years
there has been growing interest in exploring the role of
atherosclerosis in the development of dementia [4], and in
several studies carotid atherosclerosis has been associated
with dementia and cognitive impairment [5–7], but there is
limited evidence shows the relationship between dementia
and carotid atherosclerosis so far [8,9].
Human paraoxonase (PON) gene family is located on the
long arm of chromosome 7 and consist of three members:
PON1, PON2 and PON3. While PON1 and PON3 are expressed in
the liver and circulates in the bloodstream, PON2 is not
detectable in serum and found in a number of tissues,
including brain, heart, liver and lung [10–12]. Paraoxonase 1
(PON1) is a calcium-dependent enzyme and attached to high-
density lipoprotein (HDL) in the blood. But some studies
demonstrate that PON 1 is also exist in the other organs like
the brain [13]. PON1 can bind reversibly to organophosphate
substrates, which it hydrolyzes. Thus it protects the nervous
system against neurotoxicity of organophosphate. Also PON1
is an antioxidant enzyme and plays an important role in the
prevention of lipid peroxidation, which lead to the develop-
ment of atherosclerosis and dementia. PON1 is able to
hydrolyze various substrates, such as paraoxon, phenylace-
tate and a wide range of lactones like Hcy-thiolactone. As a
natural substrate Hcy-thiolactone, because metabolic conver-
sion of homocysteine to thiolactone and protein homocystei-
nylation by thiolactone may play a role in homocysteine-
induced vascular damage, inﬂammation and in conclusion
atherosclerosis [11,14–16] also N-homocysteinylation of HDL
and PON1 leads to loss of function [17]. Previous studies have
shown that low serum PON1 activity is a risk factor for AD
[18,19].
Many previous studies have focused on the relationship
between AD and PON1 polymorphisms (two most commonly
studied PON1 polymorphisms, M55L and Q192R, inﬂuence
PON1 function). Some of these studies suggested a positive
relationship between PON1 polymorphism and AD [20]
whereas some studies suggested no relationship [21]. In most
of these studies serum PON1 activity or concentration did not
measure.
Thus, it is seen that the relationship between PON1
polymorphisms, serum PON1 activity, carotid atherosclerosis
and AD is not clear and it is important to evaluate PON1
activity and carotid atherosclerosis, which are the risk factors
for AD. There are no studies investigating the relationship
between PON1 activity and carotid atherosclerosis in Alzhei-
mer's disease. Therefore we aimed to evaluate the relationshipbetween the serum PON1 activity and carotid atherosclerosis
in patient with AD and control group who have carotid
atherosclerosis but non-demented.
2. Materials and methods
The present study included 25 patients diagnosed with
Alzheimer's disease according to the criteria of NINCDS-
ADRDA (National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer's Disease and
Related Disorders Association) in the Van Regional Training
and Research Hospital Neurology Department [22]. Some
criteria were considered during the selection of study
participants. These are having dementia determined by
clinical examination and mental state tests, deterioration in
a minimum of two cognitive domains, progressive cognitive
destruction also including the memory, normal state of
consciousness, and not having other medical or neurological
diseases that could lead to the disease. Study exclusion criteria
were: (1) systemic diseases with effect on cognitive functions;
(2) brain diseases with an effect on cognitive functions; (3)
psychiatric diseases with effect on mental state.
The patient and the control groups were administered
standardized mini mental test state examination (MMSE), and
the scores between 24 and 30 were rated as mild cognitive
disorder, the scores between 20 and 23 as early AD, the scores
between 10 and 19 as moderate AD, and the scores between 0
and 9 as severe AD based on the MMSE test. Individuals with a
MMSE scores between 9 and 23 were included in the study as
patient group. The MMSE scores of the subjects in the control
group was over of 30. The recorded parameters included
routine biochemical and hematological tests requested from
every patient for studying at the clinical biochemistry
laboratory of our hospital (fasting blood glucose, urea,
creatinine, sodium, potassium, calcium, total cholesterol,
triglyceride, HDL, LDL-low density lipoprotein, hemogram,
hourly erythrocyte sedimentation rate, ﬁbrinogen, thyroid
function tests (T3, T4, TSH), vitamin B12 and folic acid). The
patients had cranial MRI (Magnetic Resonance Imaging) and
carotid artery USG examinations for plaque formation. In the
patient group, there were 4 female and 21 male patients, with a
mean age of 70.96  5.863 (min: 61, max: 83) years. The control
group included 25 individuals within the same age group as
the patient group, who had carotid artery plaque and had no
neurological diseases as determined by radiological and
neurological examinations. In this group, there were 5 female
and 20 male patients, with a mean age of 71.56  5.447 (min:
65, max: 81) years. All patients were informed about the details
of the study and written consent was obtained. All procedures
were performed in concordance with the ethical standards of
the Declaration of Helsinki. Prior to the study, approval was
obtained from Van Regional Training and Research Hospital
Non-Invasive Clinical Researches Ethics Committee.
In a semidark room, all subject lay supine with their necks
slightly hyperextended and rotated away from the imaging
transducer and the right and left carotid arteries and the
bifurcation were imaged by an experienced radiologist via an
ultrasonography device (Hitachi) using a 10–12-MHz linear
probe. The existing plaque was measured by involving the ﬁrst
Fig. 1 – Calcified atheroma plaque in carotid artery on USG.
Fig. 2 – Measurement of carotid plaque at the axial plane on
USG.
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Measurement was performed for both main carotid arteries.
Then, these values were evaluated individually and by
averaging (Figs. 1 and 2). MRI assessment was made in
accordance with the cranial MRI (1.5 Tesla GE signa) protocol in
patients with neurologically suspected Alzheimer's disease in
clinical terms.
Following a 12-h fasting period, from each of the patients
and healthy controls, 10 ml of antecubital blood was taken as
5 ml into regular biochemistry tube and 5 ml into EDTA tube,
and EDTA blood samples were immediately stored on ice at
4 8C. The serum samples were then separated from the cells by
centrifugation at 3000 rpm for 10 min. The serum samples
were stored at 80 8C and used to analyze the PON1 activity
and homocystein levels.
PON activity was determined spectrophotometrically with
using paraoxon as the substrate. The serum sample to be
tested was added to a cuvette containing 1 mM paraoxon (O,O-
dietil-O-p-nitrofenilfosfat), 1 mM CaCl2, and 50 mM glycine/
NaOH buffer at pH 10.5. The amount of p-nitrophenol
generated was calculated from the molar extinction coefﬁcientat pH 10.5, which was 18,290 mol1cm1. PON1 activity was
expressed as the U/l required to generate 1 mM p-nitrophenol
in 1 min under well-established conditions. The rate of
hydrolysis of paraoxon was measured by monitoring the
increase in absorbance at 412 nm and 25 8C due to the
formation of p-nitrophenol [23]. Serum homocysteine level
was determined by the method of enzyme-linked immuno-
sorbent assay (ELISA) using the Axis Homocysteine EIA kit and
results is expressed as mmol/L.
3. Statistical analysis
Among the speciﬁcations considered, the descriptive statistics
for continuous variables were expressed in mean and standard
deviation, whereas the categorical variables were expressed in
numbers and percentage. For continuous variables, the group
means were compared using the student's t-test. The
relationship between the groups and the categorical variables
was established using the chi-square test. Between the
relationship PON 1 activity and carotid atherosclerosis was
investigated by the Spearmen correlation test. The results
were considered statistically signiﬁcant when P < 0.05. The
data were analyzed using the SPSS® for Windows computing
program (Version 11.0).
4. Results
Basic characteristics of the study group and the laboratory
parameters are presented in Table 1. The educational status of
the study participants were categorized as elementary school,
high school and university, and the average of the education
duration was established for both groups. There was no
signiﬁcant difference in total cholesterol, HDL, LDL, and serum
glucose levels between the patient and the control groups. The
mean paraoxonase activity (31.06  2.31 U/L) was signiﬁcantly
lower in the patient group compared to the control group (59.05
 7.05 U/L) (P < 0.001). Serum homocystein levels was higher in
the patient group (22.15  7.05) compared to the control group
(13.30  3.32). The carotid plaque value was signiﬁcantly higher
in the patient group (3.02  0.52 mm) compared to the control
group (1.84  0.45 mm) (P < 0.001). Furthermore, there was a
negative correlation (81.0%) between PON1 activity and carotid
plaque in the overall study group (P < 0.05).
The relationship between the paraoxonase activity and
carotid atherosclerosis are presented in Table 2. It was found
an inverse correlation coefﬁcient between the paraoxonase
activity and carotid atherosclerosis in the overall study group (
r = 0.81) (P < 0.05).
Plaque formation details of both groups are presented in
Table 3. Accordingly, 1 subject (4%) in the control group had
ﬁbro-fatty plaque formation, whereas 24 subject (96%) had
calciﬁed plaque formation. Ulcerated plaque formation was
not detected in the control group subjects. In the patient group,
8 patients (32%) had ﬁbro-fatty plaque formation, 13 patients
(52%) had calciﬁed plaque formation, and 4 patients (16%) had
ulcerated plaque formation.
Some Alzheimer's patients of images of the carotid artery
ultrasound and MRI brain shown in the Figs. 1–3. In Fig. 1
Table 1 – Basic characteristics and biochemical parameters of the study group.
Characteristics Patient (n = 25) Controls (n = 25) P
Age (y) 70.96  5.8 71.56  5.4 n.s
Female/male 4/21 5/20 n.s
SBP (mm Hg) 140.7  15.3 125  10.4 n.s
DBP (mm Hg) 80.6  10.1 75  12.3 n.s
Total cholesterol (mmol/L) 6.2  1.42 5.8  1.01 n.s
LDL cholesterol (mmol/L) 3.75  1.05 3.47  0.90 n.s
HDL cholesterol (mmol/L) 1.46  0.33 1.35  0.41 n.s
Homocystein (mmol/L) 22.15  7.05* 13.30  3.32 0.001
Serum glucose (mmol/L) 6.0  1.4 5.5  1.3 n.s
PON1 activity (U/L) 31.06  2.31* 59.05  7.05 0.001
Carotid plaque (mm) 3.02  0.52* 1.84  0.45 0.001
Smoking (yes/no) 6/19 4/21 n.s
Alcohol consumption (yes/no) no no n.s
Statin therapy (yes/no) 2/23 0/25 n.s
Level of education (years  SD) 6.5  4.3 8.1  4.2 n.s
Abbreviations: SBP: Systolic blood pressure, DBP: Diastolic blood pressure; HDL: high density lipoprotein; LDL: Low density lipoprotein. Values
are means  standard deviation and number of cases. n.s., non-signiﬁcant.
* It implies the statistical signiﬁcance between patients and control group (P < 0.001).
Table 2 – The relationship between the paraoxonase activity and carotid atherosclerosis.
n Mean  Std. deviation Min. Max. r correlation coefﬁcient P
Paraoxonase 50 45.60  14.96 27.45 66.72 0.81 0.001
Carotid plaque 50 2.41  0.77 1.00 4.00
Table 3 – Plaque formation details of patient and control groups.
Plaque formation total
Fibro-fatty Calciﬁed Ulcer
Total
Control group (number and percentage) 1 (4%) 24 (96%) 0 (0%) 25
Patient group (number and percentage) 8 (32%) 13 (52%) 4 (16%) 25
Chisquare = 12.715.
Fig. 3 – Evident atrophy in the cerebral structures on the
sagittal T2-weighted MR image in a Alzheimer's patient.
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by ultrasound examination. Measurement of carotid plaque
are shown in Fig. 2 with the USG in the axial plane and in Fig. 3
It is seen evident atrophy in the cerebral structure on the
sagittal T2-weighted MR image in a patient with Alzheimer's
disease.
5. Discussion
Alzheimer's disease has a fast growing incidence in the world-
wide recent years. Therefore studies related to Alzheimer's
disease has increased in recent years. So far, the etiopatho-
genesis of disease has not been fully clariﬁed but some risk
factors such as age, family history, hypertension, carotid
atherosclerosis and presence of APOE 24 allele has emerged as
an important risk factors for disease [3,24,25].
PON 1 is an enzyme have many important physiologic
activities, but mechanisms underlying physiological roles of
PON1 and its related neurologic disease are not fully under-
stood [26]. PON1 is believed to have antiatherogenic features
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participate in atherosclerosis prevention; antioxidant protec-
tion, prevent lipoproteins, particularly LDL from oxidative
modiﬁcation and hydrolysis of homocysteine thiolactone
[28,29]. Hcy-thiolactone is a reactive metabolite formed with
the metabolized of homocysteine by methionyl-tRNA synthe-
tase [30]. Hcy-thiolactone can changes protein lysine residues
in a process called as N-homocysteinylation and N-Homo-
cysteinylation affects protein structure and function. There-
fore substances in protein structure such as enzymes may lose
their activity. Because of PON1 have Hcy-thiolactonase
activity, it can protects protein structure and function from
harmful effect of N-homocysteinylation [15]. Thus, PON 1 play
a protective role against atherosclerosis by detoxiﬁed Hcy-
thiolactone [31]. Previous studies have shown that N-Homo-
cysteinylation is associated with atherosclerosis and Alzhei-
mer's disease [32,33].
The present study found signiﬁcantly lower level of serum
PON 1 activity in Alzheimer's patients (31.06  2.31) compared
to the control group (59.05  7.05). On the contrary serum
homocystein level was higher in Alzheimer's patients (22.15
 7.05) compared to the control group (13.30  3.32). The
carotid plaque thickness values were higher in the patient
group (3.02  0.52) compared to the control subjects within the
same age group (1.84  0.45) (P < 0.001). Furthermore, there
was a negative correlation (81.0%) between PON1 activity and
carotid plaque in the overall study group (P < 0.05). Also in our
study we did not observe signiﬁcant total cholesterol or LDL
cholesterol levels differences between AD group and the
control group. When the literature was reviewed, no other
study was identiﬁed, which evaluated the relationship
between PON1 activity and carotid plaque thickness in AD.
However, this relationship has been investigated in various
diseases. For instance, the relationship between PON1 and
carotid intima media thickness (carotid atherosclerosis) was
investigated by Harangi et al. [34] in individuals aged below 55
with carotid artery disease; by Yang et al. [35] in hypertensive
patients and all established a negative correlation between
these two variables.
The low PON1 activity may be due to various reasons in
Alzheimer's patients. First, PON 1 activity may have fallen due
to high serum homocysteine levels (because of homocystei-
nylation) [17]. Second it is known that the polymorphism in the
PON1 gene may affect the enzyme activity. [20,21]. But we
couldn't perform to analysis PON1 genotype of Alzheimer's
patient due to technical problems.
According to our knowledge, there are three studies
examining the PON1 activity in patient with Alzheimer's
disease. The ﬁrst one is the study by Paragh et al. [18] and they
found signiﬁcantly lower PON1 activity in Alzheimer's patients
compared to the control group. In a similar, Wehr et al. [19]
found lower PON1 activity in Alzheimer's patients compared
to the control group. The ﬁndings of these two studies are
consistent with the present study. On the other hand Dantoine
et al. have found no difference for PON1 activity between the
AD and control group [36].
Atherosclerosis is a chronic inﬂammatory disease and
considered the most important sign of vascular pathologies
that are common in the aging population [37]. Atherosclerosis-
related carotid stenosis have been established in 75% of malesand 62% females, respectively, who are aged 65 and above.
Oxidative stress plays an important role in the pathogenesis of
atherosclerosis. Some oxidative stress markers such as
paraoxonase 1, homocysteine, Asymmetric dimethylarginine
(ADMA) and oxidized low-density lipoprotein (oxLDL) have
been related to the progression and development of athero-
sclerosis [38,39]. The earliest lesion of atherosclerosis is the
fatty streaks characterized by intracellular lipid accumulation
in macrophages and smooth muscle cells in the vascular wall,
which can be seen in children and infants [40]. Such changes
start in the early periods of life. It slowly progresses to the
intermediate form, ﬁbro-fatty lesions, with the effect of
hypercholesterolemia, and ﬁbrous or atheromatous plaque
develops ultimately. In brief, atherosclerosis occurs in three
stages as asymptomatic period characterized by the fatty
streaks in childhood and young adulthood, symptomatic and
ischemic periods in which the plaque undergoes degenerative
changes and results in hemorrhage, ulceration, calciﬁcation,
and thrombosis [41]. Increased carotid intima media thickness
(IMT) is considered an important marker of atherosclerosis [42]
and high-resolution B-mode ultrasonography has today
become a commonly used, reliable method to identify and
follow the changes in the carotid intima media thickness and
carotid atherosclerosis [43]. Important studies have been
conducted speciﬁcally in the last decade regarding the
relationship between carotid atherosclerosis and dementia.
Three of these studies, Cardiovascular Health Study [8], the
Rotterdam Study [7] and recently-conducted Baltimore Lon-
gitudinal Study of Aging [9], are prospective and large-scale
studies suggesting that carotid atherosclerosis is an important
risk factor for dementia including Alzheimer's disease. All of
these three studies followed-up the study participants for a
long time and concluded that the individuals with an IMT
value (carotid plaque) only in the top quintile (threshold effect)
developed dementia. As mentioned above, the present study
found higher carotid plaque values in Alzheimer's patients
compared to the control group and therefore, our ﬁndings are
consistent with these studies. It has been suggested that
chronic hypoperfusion may underlie the relationship between
dementia, particularly Alzheimer's, and atherosclerosis. It has
been also claimed that the structural changes slowly occurring
in the cerebral veins due to atherosclerosis impair cerebral
perfusion and this leads to subclinical vascular brain diseases
[44,45].
There are some limitations in this study. First, the studied
population was small. It would be appropriate to planning of
research with larger sample size for verify the relationship
between PON1 activity and carotid atherosclerosis in Alzhei-
mer's patients. Secondly, the activity of PON1 is under genetic
and environmental regulation. We couldn't perform PON1
genotype analyses due to technical challenges. Despite these
limitations, our study, we believe that the preliminary study
showing the relationship between carotid atherosclerosis and
PON1 activity in patients with AD.
In conclusion, there is an inverse relationship between the
serum PON 1 activity and development of carotid plaques in
patients with AD. The lower the PON1 activity the more
progressed the atherosclerotic process in AD. Therefore, it is
important to measure the serum PON1 activity and to evaluate
the carotid plaques in individuals with advanced age. So that
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 4 0 3 – 4 0 9408these easy, inexpensive and noninvasive markers may
improve the ability to identify individuals at high risk of
future dementia.
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